Clinical trial · Observational
Network Pharmacology Prediction: Mechanism Study of Puerarin in the Treatment of Giant Cell Tumors of Bone
Treatment of Giant Cell Bone Tumor With Purerin: New Insights From Network Pharmacology, Bioinformatics Analysis, and Experimental Verification
NCT06331104CI-TRIAL-00075628completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Based on network pharmacology analysis, this study aims to explore the potential therapeutic targets and molecular mechanisms of puerarin on giant cell tumor of bone (GCTB) genes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Giant Cell Tumors | Giant Cell Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gene expression levels | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- P27 expression groups
- description
- 12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).
- interventionNames
- Genetic: gene expression levels
- label
- ESR1 expression groups
- description
- 12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).
- interventionNames
- Genetic: gene expression levels
Primary outcomes (2)
- measure
- P27 expression levels
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Diagnosed as a patient with giant cell tumor of bone; 2. Performing surgical treatment in 1st hospital of SYSU; 3. Having complete clinical registration information; 4. Preserve surgical or puncture specimens; Exclusion Criteria: 1. Non bone giant cell tumor patients; 2. No surgical treatment was performed; 3. Incomplete clinical information registration; 4. No preserved surgical or puncture specimens.
References
Publications (0)
Data not yet available
No reference posted for this study.